22084-94-2

Usage

Uses

Used in Pharmaceutical Development:
7-Methoxy-8-hydroxy-4-Methylcoumarin is used as a pharmaceutical candidate for its potential antioxidant, anti-inflammatory, and anticancer properties. Its ability to modulate various biological pathways makes it a valuable asset in the development of new drugs for treating a range of diseases.
Used in Neurodegenerative Disease Treatment:
In the field of neurology, 7-Methoxy-8-hydroxy-4-Methylcoumarin is used as a potential treatment for neurodegenerative diseases due to its neuroprotective properties. Its capacity to mitigate oxidative stress and inflammation may contribute to slowing down the progression of these diseases.
Used in Antimicrobial Applications:
7-Methoxy-8-hydroxy-4-Methylcoumarin is used as an antimicrobial agent, leveraging its ability to inhibit the growth of various microorganisms. This property makes it a candidate for the development of new antibiotics to combat drug-resistant bacteria.
Used in Antiviral Applications:
In the field of virology, 7-Methoxy-8-hydroxy-4-Methylcoumarin is used as an antiviral agent, exhibiting potential to inhibit viral replication and infection. Its antiviral activity positions it as a candidate for the development of new antiviral drugs to address emerging viral threats.
Used in Biotechnology Research:
7-Methoxy-8-hydroxy-4-Methylcoumarin is used in biotechnology research for its potential applications in various fields, including drug discovery, disease treatment, and the development of novel therapeutic agents. Its diverse biological activities make it a valuable tool for exploring new avenues in biotechnological applications.

Upstream product

• 2107-77-9 4-methyldaphnetin 
• 74-88-4 methyl iodide 
• 934-00-9 3-methocycatechol 
• 141-97-9 ethyl acetoacetate 
• 77-78-1 dimethyl sulfate 

Relevant academic research and scientific papers

Synthesis and structure-activity relationship of coumarins as potent Mcl-1 inhibitors for cancer treatment

Myeloid cell leukemia-1 (Mcl-1) is a validated and attractive target for cancer therapy. Over-expression of Mcl-1 in many cancers allows cancer cells to evade apoptosis and contributes to their resistance to current chemotherapeutics. In this study, more than thirty coumarin derivatives with different substituents were designed and synthesized, and their Mcl-1 inhibitory activities evaluated using a fluorescence polarization-based binding assay. The results showed that the catechol group was a key constituent for Mcl-1 inhibitory activity of the coumarins, and methylation of the catechol group led to decreased inhibitory activity. The introduction of a hydrophobic electron-withdrawing group at the C-4 position of 6,7-dihydroxycoumarin, enhanced Mcl-1 inhibitory capacity, and a hydrophilic group in this position was unbeneficial to the inhibitory potency. In addition, the introduction of a nitrogen-containing group to the C-5 or C-8 position, which allowed an intramolecular hydrogen bond, was also unfavorable for Mcl-1 inhibition. Among all coumarins tested, 4-trifluoromethyl-6,7-dihydroxycoumarin (Cpd 4) displayed the most potent inhibitory activity towards Mcl-1 (Ki = 0.21 ± 0.02 μM, IC50 = 1.21 ± 0.56 μM, respectively), for which the beneficial effect on taxol resistance was also validated in A549 cells. A strong interaction between Cpd 4 and Mcl-1 in docking simulations further supported the observed potent Mcl-1 inhibition ability of Cpd 4. 3D-QSAR analysis of all tested coumarin derivatives further provides new insights into the relationships linking the inhibitory effects on Mcl-1 and the steric-electrostatic properties of coumarins. These findings could be of great value for medicinal chemists for the design and development of more potent Mcl-1 inhibitors for biomedical applications.

High-selectivity preparation method for 7-methoxy-6/8-hydroxy coumarin

The invention provides a high-selectivity preparation method for 7-methoxy-6/8-hydroxy coumarin and belongs to the field of synthesis of natural medicines. The method comprises the steps of subjecting a catechol coumarin compound to a high-selectivity methylation reaction with a methylation reagent in a proper base catalyst added organic reaction system, so as to obtain a 7-hydroxyl mono-methylate, wherein the mole ratio of a base to the catechol coumarin compound is (2.0 to 7.0): 1, the mole ratio of the methylation reagent to the catechol coumarin compound is (1.0 to 3.0): 1, the temperature of the organic reaction system is 0 DEG C to 30 DEG C, and the reaction time is 1.0 to 5.0 hours. The method has the characteristics of simplicity in operation, moderate conditions, good selectivity, high yield and the like and can be applied to the preparation of mono-methylates of coumarin catechols with different types of substituents.